knowledge -WSS

knowledge

author：hotspot 2025-09-27 12:54:37 - browse：13887

There are a lot of reasons why updated data on Pfizer’s Lorbrena, a treatment for non-small cell lung cancer, might not seem to be a big deal. The results are an update on the clinical trial that resulted in the Food and Drug Administration granting Lorbrena full approval in 2001, so in a sense they are not even that new. For Pfizer investors, Lorbrena isn’t that big a deal, either. The medicine, for patients whose lung tumors have particular genetic mutations, generated only $575 million last year — an amount that is up 57% from the year prior, but that still constitutes only 1% of the drug giant’s annual sales.

But there is one number that makes the Lorbrena data quite eye-catching: In the updated data, the daily pill decreased the risk that cancer would progress or that a patient would die by 81% over five years.

That’s a stunning number, especially when one considers that Lorbrena was not being compared to an inert placebo but to Xalkori, another Pfizer targeted cancer drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： At ASCO, AstraZeneca reports strong data for breast cancer drug

hotspot

WSS

Eli Lilly expects to double planned employment in Boston center

The EU Joint Clinical Assessment needs to live up to its promise

STAT Summit: Michael J. Fox on progress in Parkinson's research

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Will Ozempic

CEOs share strategies for surviving biotech slump

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Trump demands the U.S. pay no more for drugs than other countries … again

STAT Summit: Michael J. Fox on progress in Parkinson's research

Continuity nursing helped my family in our darkest PICU moments

Lawmakers consider Medicare pay reforms for doctors

Affirmative action in medical school literally saved lives

Eli Lilly expects to double planned employment in Boston center

The cancer drug shortage isn’t new — and neither are the solutions

Hospital price transparency does save money, advocate argues

entertainment

Kaiser's Risant Health gobbled up Geisinger. Who is next?

STAT Summit: Biotech founders on deal

With trial win, GSK could get blood cancer drug back on market

STAT Summit: Biotech founders on deal

UnitedHealth’s board chair also owns a personal investment firm

Woman returns to dialysis after doctors remove transplanted pig kidney

hotspot

hotspot

hotspot

Wikipedia